Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease

被引：34

作者：

Valgimigli, Marco ^{[1
,2
]}

Aboyans, Victor ^{[3
,4
]}

Angiolillo, Dominick ^{[5
]}

Atar, Dan ^{[6
,7
]}

Capodanno, Davide ^{[8
]}

Halvorsen, Sigrun ^{[9
,10
]}

James, Stefan ^{[11
]}

Juni, Peter ^{[12
,13
]}

Kunadian, Vijay ^{[14
]}

Landi, Antonio ^{[1
,2
]}

Leonardi, Sergio ^{[15
,16
]}

Mehran, Roxana ^{[17
]}

Montalescot, Gilles ^{[18
]}

Navarese, Eliano Pio ^{[19
]}

Niebauer, Josef ^{[20
]}

Oliva, Angelo ^{[21
]}

Piccolo, Raffaele ^{[22
]}

Price, Susanna ^{[23
]}

Storey, Robert F. ^{[24
]}

Voeller, Heinz ^{[25
]}

Vranckx, Pascal ^{[26
,27
]}

Windecker, Stephan ^{[28
]}

Fox, Keith A. A. ^{[29
]}

机构：

[1] Cardioctr Ticino Inst, Div Cardiol, Ente Ospedaliero Cantonale, Via Tesserete 48, CH-6900 Lugano, Switzerland

[2] Univ Italian Switzerland, Dept Biomed Sci, Switzerland, Switzerland

[3] Dupuytren Univ Hosp, Dept Cardiol, 2Martin Luther King ave, F-87042 Limoges, France

[4] Dupuytren Univ Hosp, INSERM 1094 & IRD, 2Martin Luther King ave, F-87042 Limoges, France

[5] Univ Florida, Div Cardiol, Coll Med Jacksonville, 655 West 8th St, Jacksonville, FL 32209 USA

[6] Univ Oslo, Oslo Univ Hosp Ulleval, Dept Cardiol, Oslo, Norway

[7] Univ Oslo, Oslo Univ Hosp Ulleval, Inst Clin Med, Oslo, Norway

[8] Univ Catania, Div Cardiol, Azienda Ospedaliero Universitaria Policlin G Rodo, Via St Sofia 78, I-95123 Catania, Italy

[9] Univ Oslo, Inst Clin Med, Blindern, POB 1078, N-0316 Oslo, Norway

[10] Oslo Univ Hosp Ulleval, Dept Cardiol, Oslo, Norway

[11] Uppsala Univ, Uppsala Clin Res Ctr, Dept Med Sci, S-75185 Uppsala, Sweden

[12] Univ Toronto, Appl Hlth Res Ctr, Li Ka Shing Knowledge Inst, St Michaels Hosp,Dept Med, Toronto, ON, Canada

[13] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada

[14] Newcastle Tyne Hosp NHS Fdn Trust, Freeman Hosp, Cardiothorac Ctr, Newcastle Upon Tyne, Tyne & Wear, England

[15] Univ Pavia, Fdn IRCCS Policlin San Matteo, Pavia, Italy

[16] Fdn IRCCS Policlin San Matteo, Coronary Care Unit, Pavia, Italy

[17] Icahn Sch Med Mt Sinai, Zena & Michael A Wiener Cardiovasc Inst, New York, NY USA

[18] Sorbonne Univ, Hop Pitie Salpetriere, AP HP, ACTION Grp,INSERM,UMRS 1166,Inst Cardiol, Paris, France

[19] Nicolaus Copernicus Univ, Dept Cardiol & Internal Med, Bydgoszcz, Poland

[20] Paracelsus Med Univ Salzburg, Inst Sports Med Prevent & Rehabil, A-5020 Salzburg, Austria

[21] Humanity Univ, Dept Biomed Sci, I-20090 Milan, Italy

[22] Univ Naples Federico II, Dept Adv Biomed Sci, Div Cardiol, Naples, Italy

[23] Royal Brompton Hosp, Natl Heart & Lung Inst, Imperial Coll, London, England

[24] Univ Sheffield, Dept Infect Immun & Cardiovasc Dis, Cardiovasc Res Unit, Sheffield, S Yorkshire, England

[25] Univ Potsdam, Fac Hlth Sci Brandenburg, Dept Rehabil Med, Potsdam, Germany

[26] Hartcentrum Hasselt, Dept Cardiol & Crit Care Med, Hasselt, Belgium

[27] Hasselt Univ, Fac Med & Life Sci, Hasselt, Belgium

[28] Univ Bern, Dept Cardiol, Inselspital, Bern, Switzerland

[29] Univ Edinburgh, Ctr Cardiovasc Sci, Div Clin & Surg Sci, Edinburgh, Scotland

来源：

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY | 2023年 / 9卷 / 05期

关键词：

Antithrombotic treatment; Coronary artery disease; Percutaneous coronary intervention; Acute coronary syndrome; Chronic coronary syndrome; DUAL-ANTIPLATELET THERAPY; ACUTE MYOCARDIAL-INFARCTION; ELUTING STENT IMPLANTATION; VEIN-GRAFT PATENCY; CLOPIDOGREL PLATELET REACTIVITY; ARTERY-BYPASS-SURGERY; PRECISE-DAPT SCORE; LONG-TERM; OPEN-LABEL; DOUBLE-BLIND;

D O I：

10.1093/ehjcvp/pvad032

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Multiple guidelines and consensus papers have addressed the role of antithrombotic strategies in patients with established coronary artery disease (CAD). Since evidence and terminology continue to evolve, the authors undertook a consensus initiative to guide clinicians to select the optimal antithrombotic regimen for each patient. The aim of this document is to provide an update for clinicians on best antithrombotic strategies in patients with established CAD, classifying each treatment option in relation to the number of antithrombotic drugs irrespective of whether the traditional mechanism of action is expected to mainly inhibit platelets or coagulation cascade. With the aim to reach comprehensiveness of available evidence, we systematically reviewed and performed meta-analyses by means of both direct and indirect comparisons to inform the present consensus document.

引用

页码：462 / 496

页数：35

共 50 条

[31] Dual pathway antithrombotic treatment and risk reduction in patients with atherosclerotic cardiovascular disease: A real-world perspective
Auer, Johann
Auer, Lisa
ATHEROSCLEROSIS, 2024, 393
[32] Antithrombotic Strategies in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
Pan, Daorong
Ren, Xiaomin
Hu, Zuoying
CURRENT PHARMACEUTICAL DESIGN, 2018, 24 (04) : 496 - 510
[33] Optimal Treatment Strategies in Patients with Chronic Kidney Disease and Coronary Artery Disease
Volodarskiy, Alexander
Kumar, Sunil
Amin, Shyam
Bangalore, Sripal
AMERICAN JOURNAL OF MEDICINE, 2016, 129 (12): : 1288 - 1298
[34] Antithrombotic Strategies in Patients With Atrial Fibrillation and Percutaneous Coronary Intervention Reply
Lopes, Renato D.
Vora, Amit N.
Alexander, John H.
JAMA CARDIOLOGY, 2021, 6 (02) : 241 - 241
[35] Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
Rajagopalan B.
Madias C.
Current Treatment Options in Cardiovascular Medicine, 2019, 21 (1)
[36] ANTITHROMBOTIC STRATEGIES IN PATIENTS ON VA ECMO AFTER PERCUTANEOUS CORONARY INTERVENTIONS
Errandi, Michelle
Looby, Mary
Albertina, Lauren
Barker, Kimberly
Lee, Thomas B.
Franke, Evan
Clevenger, Lindsay
Gannon, Michelle
Young, Karl D.
Alkalbani, Mutaz
Vavilin, Ilan
Truesdell, Alexander
Tehrani, Behnam
Buchner, Jessica
King, Christopher S.
CHEST, 2024, 166 (04) : 6392A - 6393A
[37] ABC of antithrombotic therapy - Antithrombotic strategies in acute coronary syndromes and percutaneous coronary interventions
Connolly, DL
Lip, GYH
Chin, BSP
BMJ-BRITISH MEDICAL JOURNAL, 2002, 325 (7377): : 1404 - 1407
[38] New antithrombotic agents for the treatment of coronary artery disease: overview
Schneider, David J.
CORONARY ARTERY DISEASE, 2012, 23 (06) : 367 - 367
[39] Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease
O'Donoghue, Michelle L.
Giugliano, Robert P.
Sabatine, Marc S.
CIRCULATION, 2023, 147 (16) : 1258 - 1259
[40] Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease
O'Donoghue, Michelle L.
Giugliano, Robert P.
Wiviott, Stephen D.
Atar, Dan
Keech, Anthony
Kuder, Julia F.
Im, KyungAh
Murphy, Sabina A.
Flores-Arredondo, Jose H.
Lopez, J. Antonio G.
Elliott-Davey, Mary
Wang, Bei
Monsalvo, Maria Laura
Abbasi, Siddique
Sabatine, Marc S.
CIRCULATION, 2022, 146 (15) : 1109 - 1119

← 1 2 3 4 5 →